Anebulo Pharmaceuticals Investor Relations Material
Latest events
Q3 2025
13 May, 2025
Q2 2025
14 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Anebulo Pharmaceuticals Inc
Access all reports
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing treatments for acute cannabinoid intoxication (ACI) and substance abuse. Its primary product candidate, ANEB-001, is a cannabinoid receptor antagonist aimed at rapidly reversing the effects of cannabinoid overdose. The company is headquartered in Lakeway, Texas, and its shares are listed on the Nasdaq.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
ANEB
Country
🇺🇸 United States